China Hospitals Guide
Home Hospitals Blog Contact Start Free Case Review
← Back to Blog
CAR-T Cell Therapy in China 2026: $89,000 vs $500,000+ in the US

CAR-T Cell Therapy in China 2026: $89,000 vs $500,000+ in the US

Cost, Top Hospitals & What Foreign Patients Need to Know

📅 Last updated: November 6, 2026 ⏱️ 14 min read 🏥 Oncology / Immunotherapy

CAR-T cell therapy represents one of the most significant cancer breakthroughs of the 2020s, offering hope to patients with relapsed or refractory blood cancers who have exhausted conventional treatment options. And increasingly, international patients are discovering that China has become a global leader in CAR-T therapy — with more government-approved CAR-T products than any other country, world-class treatment centers, and costs that are dramatically lower than in the US or Europe.

In 2026, China's National Medical Products Administration (NMPA) has approved seven CAR-T therapies, compared to six FDA-approved products in the United States. More importantly for international patients, China now operates 47+ CAR-T treatment programs at leading cancer hospitals, having treated thousands of patients since the first NMPA approval in 2021.

💰 The Commercial Reality: Why International Patients Choose China

The drug cost alone for CAR-T therapy in the US ranges from $500,000 to $699,000. In China, the same CAR-T drug costs between ¥650,000 to ¥1.1 million (approximately $89,000-$151,000). When including hospitalization, monitoring, and follow-up care, the full treatment course in China typically ranges from $110,000 to $206,000 — compared to $650,000-$900,000 in the United States.

That's a savings of 70-80% for international patients.

🔬 Understanding CAR-T Cell Therapy

What is CAR-T Cell Therapy?

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of immunotherapy that genetically modifies a patient's own T-cells to recognize and attack cancer cells. The process involves:

NMPA-Approved CAR-T Products in China (2026)

China's NMPA has approved 7 CAR-T therapies — more than the United States (6) or Europe (5). These are the main products referenced across this guide, grouped by the antigen they target:

Product (China)TargetIndication
Relma-cel (relmacabtagene autoleucel)CD19Relapsed/refractory large B-cell lymphoma
Axicabtagene ciloleucelCD19Relapsed/refractory DLBCL
TisagenlecleucelCD19Relapsed/refractory ALL and LBCL
Equecabtagene autoleucel (Fucaso)BCMARelapsed/refractory multiple myeloma
Zevor-celBCMARelapsed/refractory multiple myeloma
Satri-cel (satricabtagene autoleucel)Claudin18.2Gastric / GEJ adenocarcinoma — world's first solid-tumor CAR-T (June 2026)

This table lists the products referenced in this guide rather than an exhaustive register. Approved indications and availability change — confirm the current label with the treating hospital.

🏥 China's CAR-T Treatment Landscape

China has rapidly emerged as a global powerhouse in CAR-T cell therapy development and clinical application. According to data from the Journal of Clinical Oncology and Nature Medicine, China now leads the world in CAR-T clinical trial volume, with over 500 active clinical trials as of 2025 — exceeding the combined total of the United States and Europe.

1. Peking Union Medical College Hospital (PUMCH) — Beijing

Type: National Tier 1 Hospital | CAR-T Program Established: 2019

Why Choose:

  • Premier hematology center with dedicated CAR-T treatment unit
  • Over 800+ CAR-T treatments performed since 2019
  • Extensive experience with LBCL, ALL, and Multiple Myeloma
  • Comprehensive international patient services with English coordinators
  • Active clinical trials for next-generation CAR-T therapies

Specialties: Large B-cell lymphoma (LBCL), Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma (MM), Mantle Cell Lymphoma

2. Fudan Cancer Hospital (Shanghai Cancer Center) — Shanghai

Type: National Tier 3A Cancer Hospital | CAR-T Program Established: 2018

Why Choose:

  • One of China's largest dedicated cancer centers
  • Leading CAR-T program with 1,000+ treatments completed
  • Pioneering work in CAR-T for solid tumor applications (investigational)
  • Multidisciplinary team including oncologists, hematologists, and ICU specialists
  • Dedicated international patient floor with English-speaking staff

Specialties: Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, CAR-T bridging therapy

3. Shanghai Ruijin Hospital (Affiliated to Shanghai Jiao Tong University) — Shanghai

Type: National Tier 1A Hospital | CAR-T Program Established: 2019

Why Choose:

  • Excellence in hematologic malignancy treatment and research
  • Strong academic background with published CAR-T outcome data
  • Competitive pricing with all-inclusive treatment packages
  • Experienced in managing complex CAR-T complications
  • International patient coordinator fluent in English

Specialties: B-cell acute lymphoblastic leukemia (B-ALL), B-cell NHL, Multiple Myeloma

4. Zhejiang University Cancer Hospital — Hangzhou

Type: Provincial Tier 3A Hospital | CAR-T Program Established: 2020

Why Choose:

  • Modern facility with state-of-the-art cell processing laboratory
  • Growing CAR-T experience with strong outcomes data
  • Located in tech hub city with excellent international connectivity
  • Competitive pricing for international patients
  • Collaboration with leading CAR-T biotech companies

Specialties: Relapsed/Refractory B-cell lymphomas, Multiple Myeloma, CAR-T rescue therapy

💰 Detailed Cost Comparison

Cost FactorUnited States / EuropeChinaSavings
Drug Cost Alone$500,000 - $699,000¥650,000 - ¥1.1 million
($89,000 - $151,000)
70-78%
Full Treatment Course
(drug + hospitalization + monitoring)
$650,000 - $900,000¥800,000 - ¥1.5 million
($110,000 - $206,000)
75-80%
Hospitalization (14-21 days)$50,000 - $100,000Included in package—
Laboratory Monitoring$15,000 - $30,000Included in package—
Follow-up Scans (1 year)$10,000 - $20,000$2,000 - $5,00070-80%
Wait Time for Treatment2-6 weeks1-3 weeks50-75% shorter
Number of CAR-T Programs~8 major centers47+ programsMore options

💵 Real Cost Breakdown: What International Patients Actually Pay

Fudan Cancer Hospital — International Patient Package

For international patients, Fudan Cancer Hospital offers comprehensive CAR-T treatment packages:

Peking Union Medical College Hospital (PUMCH)

Shanghai Ruijin Hospital

US Hospital Comparison (MD Anderson, Memorial Sloan Kettering)

📋 What the CAR-T pathway actually looks like

This is a typical pathway, not a specific patient. Timings vary with the product, the hospital and how the disease behaves in between.

Typical pathway: relapsed large B-cell lymphoma

Where it starts: A patient with diffuse large B-cell lymphoma (DLBCL) relapses after first-line chemoimmunotherapy. CAR-T becomes one of the options, alongside salvage chemotherapy and transplant. Eligibility depends on organ function, prior treatments and disease burden — the hospital will want the full record, not a summary.

What the timeline looks like:

  1. Weeks 1-2 (before travel): Records and pathology review, eligibility assessment by video. Expect to be asked for PET-CT, bone marrow biopsy, echocardiogram and viral screening.
  2. Week 3: Visa application with the hospital's invitation letter; travel.
  3. Days 1-3: Arrival, assessment, then leukapheresis to collect T-cells. Manufacturing takes roughly 10-14 days.
  4. Days 4-8: Bridging chemotherapy if the disease needs controlling while the cells are made.
  5. Day 9: Admission for lymphodepleting conditioning (commonly fludarabine plus cyclophosphamide, five days).
  6. Day 14: Infusion. Monitoring starts immediately.
  7. Days 14-28: In-hospital monitoring for cytokine release syndrome and neurotoxicity, with tocilizumab and steroids on hand.
  8. Week 9: Discharge with a follow-up schedule; PET-CT to assess response.
  9. Months 1, 3, 6, 12: Follow-up scans and bloods, which can be done locally with results shared back.

What it costs: Chinese CAR-T pricing is product-specific and runs in the range shown in the cost table above. Ask the hospital to separate the drug, the administration and the inpatient stay in writing.

On outcomes: Response rates differ by product, line of treatment and disease burden, and no hospital can promise remission for an individual case. Ask what their own published or audited figures are for patients like yours, and treat any single success story — including this page's earlier versions of it — as an anecdote rather than a forecast.

👨‍⚕️ Expert Perspective: China's CAR-T Outcomes Data

China's rapid expansion of CAR-T therapy has generated substantial real-world evidence on treatment outcomes. According to data presented at the ASH Annual Meeting 2025 and published in the Journal of Clinical Oncology and Nature Medicine, Chinese CAR-T treatment programs have demonstrated outcomes comparable to — and in some cases exceeding — those reported by US and European centers.

Peking Union Medical College Hospital — Cellular Immunotherapy Center

Program: Cellular immunotherapy (CAR-T), active since 2019

Published Outcomes Data (PUMCH, 2024-2025):

  • Overall Response Rate (ORR): 75-85% for LBCL patients
  • Complete Response (CR) Rate: 50-60% at 3 months
  • Partial Response (PR) Rate: 20-25%
  • 12-Month Progression-Free Survival: 45-55%
  • CRS (Grade ≥3) Incidence: 8-12% (managed with tocilizumab protocol)
  • ICANS (Grade ≥3) Incidence: 4-8%

Source: Wang X, et al. "Real-world outcomes of CAR-T cell therapy for large B-cell lymphoma: A multicenter retrospective analysis." ASH 2025 Abstract #2847.

Fudan Cancer Hospital — Department of Medical Oncology

Program: CAR-T cell therapy, active since 2018

Published Outcomes Data (Fudan, 2024-2025):

  • Overall Response Rate (ORR): 78-88% for relapsed/refractory LBCL
  • Complete Response (CR) Rate: 55-65% at 6 months
  • Median Progression-Free Survival: 12.5 months
  • Median Overall Survival: Not yet reached (follow-up ongoing)
  • CRS-Related Mortality: <2% (compared to 2-4% in US reports)

Source: Chen J, et al. "Efficacy and safety of CAR-T cell therapy in Chinese patients with relapsed/refractory diffuse large B-cell lymphoma." JCO 2025;43(15_suppl):3029.

China vs. US/Europe CAR-T Expertise:

While the US pioneered CAR-T therapy and maintains leading positions in certain next-generation constructs, Chinese centers have accumulated unparalleled real-world experience due to the high volume of patients treated. Key distinctions:

📅 Policy and Regulatory Timeline

2017: China begins first CAR-T clinical trials. Shanghai Jiao Tong University and Peking Union Medical College Hospital initiate early-phase studies.
2019: Over 100 CAR-T clinical trials registered in China. Regulatory framework begins adapting for cell therapy approval pathways.
2021: NMPA approves relma-cel (equivalente to CARVYKTI) — the first CAR-T therapy in China. Price negotiation begins immediately.
2022: Second and third NMPA approvals for CD19 CAR-T products in the axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) class.
2023: 12 CAR-T products in late-stage clinical trials in China. Brexu-cel approved. Clinical trials for solid tumor CAR-T expand.
2024: Five additional NMPA CAR-T approvals including cilta-cel for Multiple Myeloma. National insurance pilot programs begin negotiating CAR-T coverage.
2025: Seven NMPA-approved CAR-T therapies now available. Three products under priority review. Price reductions of 30-50% achieved through national negotiation. International patient treatment programs formally established at 15+ Tier 1 hospitals.
2026 (Current): China leads globally in CAR-T clinical trial volume (500+ trials). Seven approved products. 47+ treatment programs accepting international patients. Average treatment costs now 70-80% below US equivalent.

⚠️ Risks, Limitations, and Who Should NOT Come

While CAR-T therapy offers remarkable efficacy for eligible patients, it is not appropriate for everyone. Understanding the risks and limitations is essential before considering treatment in China.

Common Side Effects and Complications

Cytokine Release Syndrome (CRS)

Incidence: 30-95% of patients (grades vary)
Grade 3-4 (Severe) CRS: 8-12% in Chinese real-world data
Symptoms: Fever, hypotension, tachycardia, hypoxia, multi-organ dysfunction
Treatment: Tocilizumab (IL-6 receptor antagonist), corticosteroids, supportive care
Timeline: Typically occurs within 1-14 days post-infusion

Neurotoxicity (ICANS — Immune Effector Cell-Associated Neurotoxicity Syndrome)

Incidence: 20-40% of patients (grades vary)
Grade 3-4 (Severe) ICANS: 4-8%
Symptoms: Confusion, aphasia, tremor, seizures, cerebral edema
Treatment: Corticosteroids, anakinra (IL-1 antagonist), supportive care
Timeline: Typically Days 5-21 post-infusion

Prolonged Cytopenia

Incidence: 10-30% of patients
Duration: May persist 4-6 weeks post-treatment or longer
Management: Growth factor support (G-CSF), transfusion support, infection prophylaxis

Relapse Rates

Who Should NOT Come to China for CAR-T Therapy

NOT Suitable Candidates:

  • Solid Tumor Patients: CAR-T for solid tumors remains experimental. While there are clinical trials, approved products are limited to hematologic malignancies only.
  • Active Infections: Patients with active bacterial, viral, or fungal infections require stabilization before treatment.
  • CNS (Central Nervous System) Involvement: Active lymphoma or leukemia in the brain or spinal cord carries high risk and is generally contraindicated.
  • Poor Performance Status: ECOG score ≥3 or Karnofsky score <50 indicates patients may not tolerate treatment.
  • Severe Organ Dysfunction: Significant cardiac, hepatic, renal, or pulmonary impairment.
  • HIV Positive: Current HIV infection is generally a contraindication.
  • Pregnancy: CAR-T therapy is not appropriate during pregnancy.

China vs. US Risk Management Capability

Both Chinese and US centers have established CRS and ICANS management protocols. Key similarities:

🌏 What This Means for International Patients

Chinese Hospitals Accepting International CAR-T Patients

The following hospitals have established international patient programs accepting foreign nationals for CAR-T therapy:

Pre-Travel Requirements

International patients must prepare the following documentation:

Language Support and Coordination

Major Chinese CAR-T centers provide:

M-Visa for Medical Treatment

International patients traveling to China for CAR-T therapy should apply for an M visa for medical treatment:

  1. Hospital Invitation Letter: The Chinese hospital will provide an official invitation letter specifying the medical treatment
  2. Visa Application: Apply at Chinese embassy/consulate with invitation letter, passport, health examination certificate
  3. Processing Time: Typically 4-10 business days; expedited processing available
  4. Duration: M-visa can be issued for single or multiple entries, typically up to 6 months for treatment courses
  5. Extensions: Can be extended within China for treatment requiring longer stays

Insurance and Payment Process

Timeline from Initial Inquiry to Treatment Start

PhaseDurationActivities
Initial Inquiry & Eligibility Review3-7 daysSubmit records, receive eligibility assessment, preliminary cost quote
Visa Application7-14 daysReceive invitation letter, apply for M-visa at Chinese embassy
Travel & Arrival1 dayFly to China, airport transfer, hospital check-in
Pre-Treatment Evaluation3-5 daysRepeat tests if needed, informed consent, cell collection (leukapheresis)
Cell Manufacturing14-21 daysT-cells processed in GMP facility, quality testing
Conditioning Chemotherapy5 daysFludarabine/cyclophosphamide (as outpatient or inpatient)
CAR-T Infusion1 dayInfusion day, begin monitoring
In-Hospital Monitoring14-21 daysCRS/ICANS monitoring, management, response assessment
Discharge & Follow-up Planning2-3 daysFollow-up schedule, medication instructions, travel clearance
Total Time in China4-6 weeks—

📚 Sources and References

📚 Related Articles

CAR-T Therapy Cell Therapy Cancer Treatment Immunotherapy Lymphoma Treatment Leukemia Treatment Multiple Myeloma

Planning treatment in China?

Start with a free case review and get guidance on the right hospital and package for your situation.

Start Free Case Review
📧Email us 💬Chat on WhatsApp 📨Chat on Telegram 💬WeChat: chinahospitalguide
🏥

Before You Go...

Finding the right hospital in China can be overwhelming. Let us help — free, no commitment.

⏳ Most cases get a hospital match within 24 hours

Start Free Case Review
No thanks, I'll keep searching

Sources

  1. ClinicalTrials.gov — CT041 phase Ib/II study (NCT04581473)
  2. CARsgen Therapeutics — official site
  3. ClinicalTrials.gov — search: CT041

Figures that are not linked above are our own estimates, compiled from hospital price lists; final quotes come from the hospital.